Zacks Investment Research Lowers OptiNose (OPTN) to Sell

Zacks Investment Research cut shares of OptiNose (NASDAQ:OPTN) from a hold rating to a sell rating in a research note released on Saturday.

According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company’s lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. “

How to Become a New Pot Stock Millionaire

Separately, Piper Jaffray Companies set a $28.00 price target on shares of OptiNose and gave the stock a buy rating in a research report on Monday, January 15th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $29.25.

OptiNose (NASDAQ OPTN) opened at $18.51 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 16.13 and a quick ratio of 15.99. OptiNose has a 52-week low of $15.01 and a 52-week high of $21.50.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Tuesday, March 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.18). sell-side analysts forecast that OptiNose will post -3 earnings per share for the current year.

In related news, CEO Peter K. Miller purchased 5,054 shares of OptiNose stock in a transaction that occurred on Friday, March 16th. The shares were acquired at an average price of $18.58 per share, for a total transaction of $93,903.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

A number of institutional investors have recently added to or reduced their stakes in OPTN. California State Teachers Retirement System acquired a new position in OptiNose during the 4th quarter valued at about $162,000. TIAA CREF Investment Management LLC acquired a new position in OptiNose during the 4th quarter valued at about $173,000. Teachers Advisors LLC acquired a new position in OptiNose during the 4th quarter valued at about $184,000. Millennium Management LLC acquired a new position in OptiNose during the 4th quarter valued at about $190,000. Finally, Deutsche Bank AG acquired a new position in OptiNose during the 4th quarter valued at about $247,000. Institutional investors own 29.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.thestockobserver.com/2018/03/21/zacks-investment-research-lowers-optinose-optn-to-sell.html.

About OptiNose

OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply